Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 10, 2011
Clinical News

CVBT-141B: Phase IIa data

BioCentury | Jan 10, 2011
Clinical News

CVBT-141B: Phase IIb data

BioCentury | Dec 6, 2010
Company News

CardioVascular BioTherapeutics, Merck deal

BioCentury | Dec 6, 2010
Clinical News

Riferminogen pecaplasmid: Phase III final data

BioCentury | Oct 11, 2010
Clinical News

SC0806 regulatory update

BioCentury | Sep 27, 2010
Finance

Regulatory milestones

Highlights of weekly biotech stock moves
BioCentury | Sep 27, 2010
Clinical News

Riferminogen pecaplasmid: Phase III data

BioCentury | Sep 23, 2010
Clinical News

Vical tumbles after ischemia miss

BioCentury | Oct 5, 2009
Clinical News

NV1FGF: Phase III complete enrollment

Items per page:
1 - 10 of 35